The effects of direct inhibition of geranylgeranyl pyrophosphate synthase on osteoblast differentiation

Journal of Cellular Biochemistry

Volumn 112, Issue 6, 2011, Pages 1506-1513

  Weivoda, Megan M ^a   Hohl, Raymond J ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b NONE   (United States)

Author keywords

digeranyl bisphophonate; geranylgeranyl; isoprenoid; statins

Indexed keywords

ALKALINE PHOSPHATASE; DIGERANYL BISPHOSPHONATE; ENZYME INHIBITOR; FARNESYL TRANS TRANSFERASE; GLUCOCORTICOID RECEPTOR; OSTEOCALCIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CALVARIA; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; ENZYME INHIBITION; ENZYME SUBSTRATE; MOUSE; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL;

ANIMALS; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELL LINE; GERANYLGERANYL-DIPHOSPHATE GERANYLGERANYLTRANSFERASE; MICE; OSTEOBLASTS; POLYISOPRENYL PHOSPHATES; POLYMERASE CHAIN REACTION;

RATTUS;

EID: 79954557143     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.23087     Document Type: Article

References (40)

1. Bang S, Yoo S, Yang TJ, Cho H, Hwang SW,. 2010. Farnesyl pyrophosphate is a novel pain-producing molecule via specific activation of TRPV3. J Biol Chem 285: 19352-19371.
2. Canalis E,. 2010. Update in new anabolic therapies for osteoporosis. J Clin Endo Metab 95: 1496-1504.
3. Canalis E, Mazziotti G, Giustina A, Bilezikian JP,. 2007. Glucocorticoid-induced osteoporosis: Pathophysiology and therapy. Osteoporos Int 18: 1319-1328. (Pubitemid 47389469)
4. Chuengsamarn S, Rattanamongkoulgul S, Suwanwalaikorn S, Wattanasirichaigoon S, Kaufman L,. 2010. Effects of statins vs. non-statin lipid-lowering therapy on bone formation and bone mineral density biomarkers in patients with hyperlipidemia. Bone 46: 1011-1015.
5. Close P, Neuprez A, Reginster JY,. 2006. Developments in the pharmacotherapeutic management of osteoporosis. Expert Opin Pharmacother 7: 1603-1615. (Pubitemid 44209604)
6. Compston J,. 2010. Osteoporosis: Social and economic impact. Radiol Clin N Am 48: 477-482.
7. Das S, Schapira M, Tomic-Canic M, Goyanka R, Cardoza T, Samuels HH,. 2007. Farnesyl pyrophosphate is a novel transcriptional activator for a subset of nuclear hormone receptors. Mol Endocrinol 21: 2672-2686. (Pubitemid 350035150)
8. Duque G, Rivas D,. 2007. Alendronate has an anabolic effect on bone through the differentiation of mesenchymal stem cells. J Bone Miner Res 22: 1603-1611. (Pubitemid 351229330)
9. Ebert R, Zeck S, Krug R, Meissner-Weigl J, Schneider D, Seefried L, Eulert J, Jakob F,. 2009. Pulse treatment with zoledronic acid causes sustained commitment of bone marrow derived mesenchymal stem cells for osteogenic differentiation. Bone 44: 858-864.
10. Endo A, Tsujita Y, Kuroda M, Tanzawa K,. 1977. Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Eur J Biochem 77: 31-36. (Pubitemid 8122952)
11. Girotra M, Rubin MR, Bilezikian JP,. 2006. Anabolic skeletal therapy for osteoporosis. Arq Bras Endocrinol Metab 50: 745-754. (Pubitemid 44786010)
12. Goldstein J, Brown MS,. 1990. Regulation of the mevalonate pathway. Nature 343: 425-430.
13. Gregory C, Gunn WG, Peister A, Prockop DJ,. 2004. An Alizarin red-based assay of mineralization by adherent cells in culture: Comparison with cetylpyridinium chloride extraction. Anal Biochem 329: 77-84. (Pubitemid 38596903)
14. Gutierrez G, Lalka D, Garrett IR, Rossini G, Mundy GR,. 2006. Transdermal application of lovastatin to rats causes profound increases in bone formation and plasma concentrations. Osteoporosis Int 17: 1033-1042. (Pubitemid 43869919)
15. Hayashi K, Yamaguchi T, Yano S, Kanazawa I, Yamauchi M, Yamamoto M, Sugimoto T,. 2009. BMP/Wnt antagonists are upregulated by dexamethasone in osteoblasts and reversed by alendronate and PTH: Potential therapeutic targets for glucocorticoid-induced osteoporosis. Biochem Biophys Res Comm 379: 261-266.
16. Holstein S, Hohl RJ,. 2004. Isoprenoids: Remarkable diversity of form and function. Lipids 39: 293-309. (Pubitemid 38971743)
17. Idris A, Rojas J, Greig IR, Van't Hof RJ, Ralston SH,. 2008. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro. Calcif Tissue Int 82: 191-201.
18. Kanis J, WHO Study Group. 1994. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Osteoporosis Int 4: 368-381.
19. Levy ME, Parker RA, Ferrell RE, Zmuda JM, Greenspan SL,. 2007. Farnesyl diphosphate synthase: A novel genotype association with bone mineral density in elderly women. Maturitas 57: 247-252. (Pubitemid 46891698)
20. Liliom K, Tsukahara T, Tsukahara R, Zelman-Femiak M, Swiezewska E, Tigyi G,. 2006. Farnesyl phosphates are endogenous ligands of lysophosphatidic acid receptors: Inhibition of LPA GPCR and activation of PPARs. Biochim Biophys Acta 1761: 1506-1514. (Pubitemid 44821912)
21. Luckman S, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ,. 1998. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13: 581-589. (Pubitemid 28163009)
22. Maeda T, Matsunuma A, Kawane T, Horiuchi N,. 2001. Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells. Biochem Biophys Res Comm 280: 874-877. (Pubitemid 32924513)
23. Maeda T, Matsunuma A, Kurahashi I, Yanagawa T, Yoshida H, Horiuchi N,. 2004. Induction of osteoblast differentiation indices by statins in MC3T3-E1 cells. J Cell Biochem 92: 458-471.
24. Marini F, Falchetti A, Silvestri S, Bagger Y, Luzi E, Tanini A, Christiansen C, Brandi ML,. 2008. Modulatory effect of farnesyl pyrophosphate synthase (FDPS) rs2297480 polymorphism on the response to long-term amino-bisphosphonate treatment in postmenopausal osteoporosis. Curr Med Res Opin 24: 2609-2615.
25. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G,. 1999. Stimulation of bone formation in vitro and in rodents by statins. Science 286: 1946-1949. (Pubitemid 129515901)
26. Nancollas G, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RGG, Ebetino FH,. 2006. Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite. Bone 38: 617-627.
27. Oh D, Yoon JM, Moon MJ, Hwang JI, Choe H, Lee JY, Kim JI, Kim S, Rhim H, O'Dell DK, Walker JM, Na HS, Lee MG, Kwon HB, Kim K, Seong JY,. 2008. Identification of farnesyl pyrophosphate and N-arachidonylglycine as endogenous ligands for GPR92. J Biol Chem 283: 21054-21064.
28. Ohnaka K, Shimoda S, Nawata H, Shimokawa H, Kaibuchi K, Iwamoto Y, Takayanagi R,. 2001. Pitavastatin enhanced BMP-2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts. Biochem Biophys Res Comm 287: 337-342. (Pubitemid 32917601)
29. Orriss I, Key ML, Colston KW, Arnett TR,. 2009. Inhibition of osteoblast function in vitro by aminobisphosphonates. J Cell Biochem 106: 109-118.
30. Ruiz-Gaspa S, Nogues X, Enjuanes A, Monllau JC, Blanch J, Carreras R, Mellibovsky L, Grinberg D, Balcells S, Diez-Perez A, Pedro-Botet J,. 2007. Simvastatin and atorvastatin enhance gene expression of collagen type 1 and osteocalcin in primary human osteoblasts and MG-63 cultures. J Cell Biochem 101: 1430-1438. (Pubitemid 47242774)
31. Sher L, Harrison JR, Adams DJ, Kream BE,. 2006. Impaired cortical bone acquisition and osteoblast differentiation in mice with osteoblast-targeted disruption of glucocorticoid signaling. Calcif Tissue Int 79: 118-125. (Pubitemid 44306169)
32. Skoglund B, Forslund C, Aspenberg P,. 2002. Simvastatin improves fracture healing in mice. J Bone Miner Res 17: 2004-2008. (Pubitemid 35239202)
33. Takase H, Yano S, Yamaguchi T, Kanazawa I, Hayashi K, Yamamoto M, Yamauchi M, Sugimoto T,. 2009. Parathyroid hormone upregulates BMP-2 mRNA expression through mevalonate kinase and Rho kinase inhibition in osteoblastic MC3T3-E1 cells. Horm Metab Res 41: 861-865.
34. Tang Q, Tran GT, Gamie Z, Graham S, Tsialogiannis E, Tsiridis E, Linder T, Tsiridis E,. 2008. Statins: Under investigation for increasing bone mineral density and augmenting fracture healing. Expert Opin Investig Drugs 17: 1435-1463.
35. Tong H, Holstein SA, Hohl RJ,. 2005. Simultaneous determination of farnesyl and geranylgeranyl pyrophosphate levels in cultured cells. Anal Biochem 336: 51-59. (Pubitemid 39593499)
36. van Beek E, Pieterman E, Cohen L, Lowik C, Papapoulos S,. 1999. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Comm 264: 108-111. (Pubitemid 29500472)
37. Vukelic S, Stojadinovic O, Pastar I, Vouthounis C, Krzyzanowska A, Das S, Samuels HH, Tomic-Canic M,. 2010. Farnesyl pyrophosphate inhibits epithelialization and wound healing through the glucocorticoid receptor. J Biol Chem 285: 1980-1988.
38. Wiemer AJ, Tong H, Swanson KM, Hohl RJ,. 2007. Digeranyl bisphosphonate inhibits geranylgeranyl pyrophosphate synthase. Biochem Biophys Res Comm 353: 921-925. (Pubitemid 46080385)
39. Yoshida T, Asanuma M, Grossmann L, Fuse M, Shibata T, Yonekawa T, Tanaka T, Ueno K, Yasuda T, Saito Y, Tatsuno I,. 2006. Geranylgeranyl-pyrophosphate (GGPP) synthase is down-regulated during differentiation of osteoblastic cell line MC3T3-E1. FEBS Lett 580: 5203-5207. (Pubitemid 44415791)
40. Zhang FL, Casey PJ,. 1996. Protein prenylation: Molecular mechanisms and functional consequences. Annu Rev Biochem 65: 241-269. (Pubitemid 26250610)